Here, we show consistently high CD123 levels on putative NPM1mut CD34+CD38− cells in patients, suggesting that anti-CD123 immunotherapies could be particularly effective in NPM1mut AML. This evidence concerns the gene CD38 and acute myeloid leukemia.